Public Company

Precision BioSciences, Inc.

Precision BioSciences utilizes its proprietary ARCUS Genome Editing method to overcome cancers, cure genetic diseases, and enable development of safer food.

About

Precision BioSciences is a clinical-stage biotechnology company dedicated to improving life with its proprietary ARCUS genome editing platform – a versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist.

Overview

Founded 2006
Type Public
Longevity related Yes
Location North Carolina, USA

Recent Jobs at Precision BioSciences, Inc.

Latest News

Stock

DTIL $12.42 -0.68% $(0.09)